The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
Lenalidomide is used to treat cancer and also some anaemia disorders
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
Subscribe To Our Newsletter & Stay Updated
